These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7032807)

  • 1. Protection of prostacyclin-like activity in human plasma-a non-enzymatic mechanism?
    Mikhailidis DP; Mikhailidis AM; Woollard ML; Dandona P
    Clin Sci (Lond); 1982 Feb; 62(2):177-81. PubMed ID: 7032807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
    Miller OV; Aiken JW; Shebuski RJ; Gorman RR
    Prostaglandins; 1980 Aug; 20(2):391-400. PubMed ID: 6251513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of prostaglandin I2 in human blood.
    Pifer DD; Cagen LM; Chesney CM
    Prostaglandins; 1981 Feb; 21(2):165-75. PubMed ID: 7012932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of renin release by 6-oxo-prostaglandin E1 and prostacyclin.
    McGiff JC; Spokas EG; Wong PY
    Br J Pharmacol; 1982 Jan; 75(1):137-44. PubMed ID: 7042021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of prostacyclin by 9-hydroxyprostaglandin dehydrogenase in human platelets. Formation of a potent inhibitor of platelet aggregation and enzyme purification.
    Wong PY; Lee WH; Chao PH; Reiss RF; McGiff JC
    J Biol Chem; 1980 Oct; 255(19):9021-4. PubMed ID: 6997309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-Keto-prostaglandin E1: its formation by platelets from prostacyclin and resistance to pulmonary degradation.
    Berry CN; Hoult JR
    Pharmacology; 1983; 26(6):324-30. PubMed ID: 6348806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of human plasma proteins on stabilisation of platelet anti-aggregatory activity of prostacyclin.
    Mikhailidis DP; Mikhailidis AM; Dandona P
    Ann Clin Biochem; 1982 Jul; 19 (Pt 4)():241-4. PubMed ID: 6181729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma prostacyclin from birth to adolescence.
    Kääpä P; Viinikka L; Ylikorkala O
    Arch Dis Child; 1982 Jun; 57(6):459-61. PubMed ID: 7046649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of circulating prostacyclin.
    Haslam RJ; McClenaghan MD
    Nature; 1981 Jul; 292(5821):364-6. PubMed ID: 7019720
    [No Abstract]   [Full Text] [Related]  

  • 10. Platelet microaggregates and release of endogenous prostacyclin during the initial phase of haemodialysis.
    Leithner C; Sinzinger H; Silberbauer K; Stummvoll HK
    Proc Eur Dial Transplant Assoc; 1981; 18():122-5. PubMed ID: 7036146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specificity between the anti-aggregatory actions of prostacyclin, prostaglandin E1 and D2 on platelets.
    Whittle BJ; Hamid S; Lidbury P; Rosam AC
    Adv Exp Med Biol; 1985; 192():109-25. PubMed ID: 2871707
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of oral contraceptives on antiaggregatory prostacyclin and proaggregatory thromboxane A2 in humans.
    Ylikorkala O; Puolakka J; Viinikka L
    Am J Obstet Gynecol; 1982 Mar; 142(5):573-6. PubMed ID: 7036746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-aggregatory prostanoids. Part I.
    Korbut R; Gryglewski RJ
    Acta Physiol Pol; 1985; 36(5-6):293-302. PubMed ID: 3915631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Release of prostacyclin into the coronary venous blood in patients with coronary arterial disease.
    Kaijser L; Nowak J; Patrono C; Wennmalm A
    Adv Myocardiol; 1983; 4():371-8. PubMed ID: 6344165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased platelet aggregability is associated with increased prostacyclin production by vessel walls in hypercholesterolemic rabbits.
    Tremoli E; Socini A; Petroni A; Galli C
    Prostaglandins; 1982 Sep; 24(3):397-404. PubMed ID: 6818616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the stability of prostacyclin in human, rabbit and rat plasma.
    El Tahir KE; Williams KI; Betteridge DJ
    Prostaglandins Leukot Med; 1983 Feb; 10(2):109-14. PubMed ID: 6342001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Release of a 6-oxoprostaglandin E1-like substance from human platelets.
    Lofts FJ; Moore PK
    Clin Sci (Lond); 1983 Jan; 64(1):63-8. PubMed ID: 6681597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary excretion rate of 6-keto-prostaglandin F1 alpha as an index of circulating prostacyclin.
    Seyberth HW; Müller H; Soeding K; Wille L; Hackenthal E
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():533-8. PubMed ID: 6221575
    [No Abstract]   [Full Text] [Related]  

  • 19. Prostaglandin E2, prostacyclin, and thromboxane changes during nonpulsatile cardiopulmonary bypass in humans.
    Faymonville ME; Deby-Dupont G; Larbuisson R; Deby C; Bodson L; Limet R; Lamy M
    J Thorac Cardiovasc Surg; 1986 Jun; 91(6):858-66. PubMed ID: 3520158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion of prostacyclin to 6 oxo prostaglandin E1 by rat, rabbit, guinea-pig and human platelets.
    Griffiths RJ; Moore PK
    Br J Pharmacol; 1983 Oct; 80(2):395-402. PubMed ID: 6360281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.